These results collectively indicate UAB36 polygenic score holds promise as a therapeutic response biomarker and an independent predictor of drug resistance risk and poor survival in ER+/HER2- breast cancer patients undergoing tamoxifen treatment. The gene discussed is ESR1; the disease is breast carcinoma.